Promotion of sleep by targeting the orexin system in rats, dogs and humans
- PMID: 17259994
- DOI: 10.1038/nm1544
Promotion of sleep by targeting the orexin system in rats, dogs and humans
Abstract
Orexins are hypothalamic peptides that play an important role in maintaining wakefulness in mammals. Permanent deficit in orexinergic function is a pathophysiological hallmark of rodent, canine and human narcolepsy. Here we report that in rats, dogs and humans, somnolence is induced by pharmacological blockade of both orexin OX(1) and OX(2) receptors. When administered orally during the active period of the circadian cycle, a dual antagonist increased, in rats, electrophysiological indices of both non-REM and, particularly, REM sleep, in contrast to GABA(A) receptor modulators; in dogs, it caused somnolence and increased surrogate markers of REM sleep; and in humans, it caused subjective and objective electrophysiological signs of sleep. No signs of cataplexy were observed, in contrast to the rodent, dog or human narcolepsy syndromes. These results open new perspectives for investigating the role of endogenous orexins in sleep-wake regulation.
Comment in
-
Orexins: looking forward to sleep, back at addiction.Nat Med. 2007 Feb;13(2):126-8. doi: 10.1038/nm0207-126. Nat Med. 2007. PMID: 17290266 Free PMC article. No abstract available.
-
Reply to 'Promotion of sleep by targeting the orexin system in rats, dogs and humans'.Nat Med. 2007 May;13(5):525-6; author reply 526. doi: 10.1038/nm0507-525. Nat Med. 2007. PMID: 17479088 No abstract available.
Similar articles
-
Orexins: looking forward to sleep, back at addiction.Nat Med. 2007 Feb;13(2):126-8. doi: 10.1038/nm0207-126. Nat Med. 2007. PMID: 17290266 Free PMC article. No abstract available.
-
Reply to 'Promotion of sleep by targeting the orexin system in rats, dogs and humans'.Nat Med. 2007 May;13(5):525-6; author reply 526. doi: 10.1038/nm0507-525. Nat Med. 2007. PMID: 17479088 No abstract available.
-
Intracerebroventricular injection of orexin-2 receptor antagonist promotes REM sleep.Behav Brain Res. 2013 Jan 15;237:59-62. doi: 10.1016/j.bbr.2012.09.015. Epub 2012 Sep 16. Behav Brain Res. 2013. PMID: 22989413
-
Orexin neuronal circuitry: role in the regulation of sleep and wakefulness.Front Neuroendocrinol. 2008 Jan;29(1):70-87. doi: 10.1016/j.yfrne.2007.08.001. Epub 2007 Aug 29. Front Neuroendocrinol. 2008. PMID: 17910982 Review.
-
Almorexant, a dual orexin receptor antagonist for the treatment of insomnia.Curr Opin Investig Drugs. 2010 Jan;11(1):101-10. Curr Opin Investig Drugs. 2010. PMID: 20047164 Review.
Cited by
-
Contactless vital signs monitoring in macaques using a mm-wave FMCW radar.Sci Rep. 2024 Jun 15;14(1):13863. doi: 10.1038/s41598-024-63994-w. Sci Rep. 2024. PMID: 38879652 Free PMC article.
-
The effect of lemborexant on insomnia in patients with psychiatric disorders: Detailed evaluation using the Athens Insomnia Scale.PCN Rep. 2024 Jan 21;3(1):e165. doi: 10.1002/pcn5.165. eCollection 2024 Mar. PCN Rep. 2024. PMID: 38868465 Free PMC article.
-
Orexinergic Receptor Antagonists as a New Therapeutic Target to Overcome Limitations of Current Pharmacological Treatment of Insomnia Disorder.Actas Esp Psiquiatr. 2024 Apr;52(2):172-182. doi: 10.62641/aep.v52i2.1659. Actas Esp Psiquiatr. 2024. PMID: 38622003 Free PMC article.
-
Pyrazole derivatives as selective orexin-2 receptor antagonists (2-SORA): synthesis, structure-activity-relationship, and sleep-promoting properties in rats.RSC Med Chem. 2023 Nov 24;15(1):344-354. doi: 10.1039/d3md00573a. eCollection 2024 Jan 25. RSC Med Chem. 2023. PMID: 38283232 Free PMC article.
-
Development of Novel 11C-Labeled Selective Orexin-2 Receptor Radioligands for Positron Emission Tomography Imaging.ACS Med Chem Lett. 2023 Sep 26;14(10):1419-1426. doi: 10.1021/acsmedchemlett.3c00320. eCollection 2023 Oct 12. ACS Med Chem Lett. 2023. PMID: 37849554 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources